Schwab Charles Investment Management Inc. lifted its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 0.4% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,035 shares of the company’s stock after buying an additional 114 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.11% of Voyager Therapeutics worth $261,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Voyager Therapeutics by 148.1% in the 2nd quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock worth $402,000 after buying an additional 26,763 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Voyager Therapeutics by 15.6% in the 1st quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock worth $582,000 after buying an additional 5,952 shares during the last quarter. Hershey Trust Co. boosted its stake in shares of Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the last quarter. Hedge funds and other institutional investors own 40.94% of the company’s stock.
WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/11/voyager-therapeutics-inc-vygr-shares-bought-by-schwab-charles-investment-management-inc.html.
VYGR has been the topic of a number of research reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a report on Friday, October 27th. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Raymond James Financial, Inc. initiated coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $28.89.
Shares of Voyager Therapeutics, Inc. (VYGR) opened at $13.60 on Friday. Voyager Therapeutics, Inc. has a 1-year low of $8.10 and a 1-year high of $25.99.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.11). The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. analysts forecast that Voyager Therapeutics, Inc. will post -3.01 earnings per share for the current year.
In other news, insider Bernard Ravina sold 10,980 shares of the company’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $20.33, for a total value of $223,223.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 32,940 shares of company stock worth $490,092. Insiders own 8.00% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGR).
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.